Literature DB >> 20585773

Comparison of diagnostic performances of three different software packages in detecting coronary artery disease.

Levent A Guner1, Nese Ilgin Karabacak, Tansel Cakir, Ozgur U Akdemir, Sinan A Kocaman, Atiye Cengel, Mustafa Unlu.   

Abstract

PURPOSE: Quantification of myocardial perfusion scintigraphy is frequently performed to assist physicians in detecting coronary artery disease (CAD). Software packages provide automated quantification of perfusion data. We aimed to compare the three commonly used software packages, Emory Cardiac Toolbox (ECT v2 and ECT v3), 4D-MSPECT (4DM v2 and 4DM v4) and Quantitative Perfusion SPECT (QPS v3 and QPS v4).
METHODS: We selected 283 patients who had a myocardial perfusion scintigraphy with (201)Tl followed by coronary angiography within 3 months. Summed stress score (SSS), summed difference score (SDS), total stress defect extent (TDE) and regional stress defect extent values were obtained from programs. A ≥70% stenosis in coronary arteries and their major branches was considered positive for CAD. A subgroup of patients was used to form an institutional normal database for QPS and 4DM. Receiver-operating characteristic (ROC) analysis to detect CAD was performed.
RESULTS: Mean SSS ± SD (vendor) for ECT v3, QPS v4 and 4DM v4 were 9.2 ± 7.1, 10.1 ± 6.8 and 5.5 ± 6.1, respectively. Area under the curve (AUC) values of SSS ROC analysis were 0.738 ± 0.031 for QPS v3, 0.755 ± 0.030 for QPS v4, 0.758 ± 0.030 for ECT v2, 0.778 ± 0.029 for ECT v3 and 0.771 ± 0.030 for 4DM v4. The AUC values for TDE were 0.755 ± 0.030 for QPS v4, 0.769 ± 0.030 for ECT v3 and 0.775 ± 0.029 for 4DM v4. The differences were not significant for both SSS and TDE. Differences of AUC between regional stress defect extent values of programs and AUC of SSS between institutional and vendor normal databases were not significant.
CONCLUSION: The diagnostic performances of programs to detect CAD are similar. However, there are differences in the magnitudes of the quantitative values produced by the programs.

Entities:  

Mesh:

Year:  2010        PMID: 20585773     DOI: 10.1007/s00259-010-1522-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  The increasing role of quantification in clinical nuclear cardiology: the Emory approach.

Authors:  Ernest V Garcia; Tracy L Faber; C David Cooke; Russell D Folks; Ji Chen; Cesar Santana
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

2.  Exercise tests. A survey of procedures, safety, and litigation experience in approximately 170,000 tests.

Authors:  P Rochmis; H Blackburn
Journal:  JAMA       Date:  1971-08-23       Impact factor: 56.272

3.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

4.  The optimal reference population for cardiac normality in myocardial SPET in the detection of coronary artery stenoses: patients with normal coronary angiography or subjects with low likelihood of coronary artery disease?

Authors:  J Toft; D Lindahl; M Ohlsson; J Palmer; A Lundin; L Edenbrandt; B Hesse
Journal:  Eur J Nucl Med       Date:  2001-07

5.  Interhospital observer agreement in interpretation of exercise myocardial Tc-99m tetrofosmin SPECT studies.

Authors:  J Candell-Riera; C Santana-Boado; B Bermejo; L Armadans; J Castell; I Casáns; J Jurado; J Magriñá; J N de la Rosa
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

6.  Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study.

Authors:  J Lette; J L Tatum; S Fraser; D D Miller; D D Waters; G Heller; E B Stanton; H S Bom; J Leppo; S Nattel
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

Review 7.  Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: a position statement.

Authors:  Claudio Marcassa; Jeroen J Bax; Frank Bengel; Birger Hesse; Claus L Petersen; Eliana Reyes; Richard Underwood
Journal:  Eur Heart J       Date:  2008-01-17       Impact factor: 29.983

8.  Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis?

Authors:  C W White; C B Wright; D B Doty; L F Hiratza; C L Eastham; D G Harrison; M L Marcus
Journal:  N Engl J Med       Date:  1984-03-29       Impact factor: 91.245

9.  Comparison of SSS and SRS calculated from normal databases provided by QPS and 4D-MSPECT manufacturers and from identical institutional normals.

Authors:  Daniela Knollmann; Ingrid Knebel; Karl-Christian Koch; Michael Gebhard; Thomas Krohn; Ulrich Buell; Wolfgang M Schaefer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-09       Impact factor: 9.236

10.  Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients.

Authors:  H Mertes; S G Sawada; T Ryan; D S Segar; R Kovacs; J Foltz; H Feigenbaum
Journal:  Circulation       Date:  1993-07       Impact factor: 29.690

View more
  12 in total

1.  Comparison of diagnostic performances of three different software packages in detecting coronary artery disease.

Authors:  Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11       Impact factor: 9.236

2.  Improving cardiac SPECT accuracy: Old robustness for a new gold standard.

Authors:  Alessia Gimelli; Riccardo Liga
Journal:  J Nucl Cardiol       Date:  2016-02-17       Impact factor: 5.952

3.  Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.

Authors:  Rami Doukky; Adebayo Olusanya; Raj Vashistha; Abhimanyu Saini; Ibtihaj Fughhi; Khaled Mansour; Abiy Nigatu; Kara Confer; Shannon A Sims
Journal:  J Nucl Cardiol       Date:  2015-04-24       Impact factor: 5.952

4.  Computerized decision making in myocardial perfusion SPECT: The new era in nuclear cardiology?

Authors:  Elin Trägårdh; Marcus Carlsson; Lars Edenbrandt
Journal:  J Nucl Cardiol       Date:  2014-12-11       Impact factor: 5.952

5.  The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging.

Authors:  Javier Gomez; Yasmeen Golzar; Ibtihaj Fughhi; Adebayo Olusanya; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2017-02-08       Impact factor: 5.952

6.  Computer-aided diagnosis system outperforms scoring analysis in myocardial perfusion imaging.

Authors:  Lena Johansson; Lars Edenbrandt; Kenichi Nakajima; Milan Lomsky; Sven-Eric Svensson; Elin Trägårdh
Journal:  J Nucl Cardiol       Date:  2014-01-18       Impact factor: 5.952

7.  Comparison of three commercially available softwares for measuring left ventricular perfusion and function by gated SPECT myocardial perfusion imaging.

Authors:  Sameer Ather; Fahad Iqbal; John Gulotta; Wael Aljaroudi; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2014-04-09       Impact factor: 5.952

8.  Quantitation of myocardial blood flow and myocardial flow reserve with 99mTc-sestamibi dynamic SPECT/CT to enhance detection of coronary artery disease.

Authors:  Bailing Hsu; Fu-Chung Chen; Tao-Cheng Wu; Wen-Sheng Huang; Po-Nien Hou; Chien-Cheng Chen; Guang-Uei Hung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-21       Impact factor: 9.236

9.  Diagnostic evaluation of three cardiac software packages using a consecutive group of patients.

Authors:  Lena Johansson; Milan Lomsky; Jens Marving; Mattias Ohlsson; Sven-Eric Svensson; Lars Edenbrandt
Journal:  EJNMMI Res       Date:  2011-09-30       Impact factor: 3.138

10.  Perfusion vector-a new method to quantify myocardial perfusion scintigraphy images: a simulation study with validation in patients.

Authors:  David Minarik; Martin Senneby; Per Wollmer; Alva Mansten; Karl Sjöstrand; Lars Edenbrandt; Elin Trägårdh
Journal:  EJNMMI Res       Date:  2015-08-14       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.